Renaissance Technologies LLC boosted its stake in Zogenix, Inc. (NASDAQ:ZGNX) by 933.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 140,441 shares of the company’s stock after acquiring an additional 126,854 shares during the quarter. Renaissance Technologies LLC’s holdings in Zogenix were worth $5,625,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. California Public Employees Retirement System boosted its stake in Zogenix by 2.4% during the 4th quarter. California Public Employees Retirement System now owns 59,150 shares of the company’s stock worth $2,369,000 after purchasing an additional 1,400 shares during the last quarter. Rhumbline Advisers raised its holdings in Zogenix by 7.5% in the 4th quarter. Rhumbline Advisers now owns 32,438 shares of the company’s stock valued at $1,299,000 after buying an additional 2,264 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Zogenix by 28.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 25,950 shares of the company’s stock valued at $1,039,000 after buying an additional 5,670 shares during the period. American International Group Inc. raised its holdings in Zogenix by 38.7% in the 4th quarter. American International Group Inc. now owns 23,057 shares of the company’s stock valued at $923,000 after buying an additional 6,434 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in Zogenix in the 3rd quarter valued at about $226,000.
Shares of NASDAQ:ZGNX opened at $40.15 on Friday. The stock has a market cap of $1,370.10, a price-to-earnings ratio of -9.99 and a beta of 1.68. Zogenix, Inc. has a 1 year low of $10.05 and a 1 year high of $45.85.
Zogenix (NASDAQ:ZGNX) last issued its quarterly earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.17). During the same period in the prior year, the firm posted ($0.95) EPS. sell-side analysts anticipate that Zogenix, Inc. will post -3.12 EPS for the current fiscal year.
Several analysts recently issued reports on the stock. BidaskClub lowered shares of Zogenix from a “buy” rating to a “hold” rating in a report on Tuesday, April 10th. ValuEngine upgraded shares of Zogenix from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research upgraded shares of Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a report on Thursday, March 15th. Leerink Swann restated an “outperform” rating on shares of Zogenix in a report on Sunday, March 4th. Finally, Mizuho restated a “buy” rating and issued a $51.00 price objective on shares of Zogenix in a report on Wednesday, March 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $53.20.
In other Zogenix news, Director Roger Hawley sold 35,000 shares of the business’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $44.71, for a total transaction of $1,564,850.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.00% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Zogenix, Inc. (ZGNX) Shares Bought by Renaissance Technologies LLC” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/15/zogenix-inc-zgnx-shares-bought-by-renaissance-technologies-llc.html.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.